Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs Morphine for Acute Sickle Cell Crisis
NCT03431285Phase 3Completed
- Sponsor
- Imam Abdulrahman Bin Faisal University
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in sickle cell disease (SCD) (2 arms), sponsored by Imam Abdulrahman Bin Faisal University. Primary endpoint: Pain Scores (NPRS). Started Jan 2018; status: completed.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03431285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431285.